OREANDA-NEWS. Roszdravnadzor has granted permission to the American pharmaceutical company Pfizer to conduct clinical trials in the Russian Federation on the effectiveness of a new drug Paxlovid, the Vedomosti newspaper writes. The company stated that the drug is able to reduce the risks of hospitalization and death due to coronavirus infection by 89%.

As noted in the state register of medicines, 90 people over the age of 18 from the Moscow region, St. Petersburg, Smolensk, Barnaul and other cities will participate in the tests. The condition is contact at home with patients who had symptoms of coronavirus infection.

Paxlovid consists of a protease inhibitor and ritonavir. Pfizer is conducting global drug trials. According to the representative of the company, seven thousand citizens of different countries, including Russia, are involved in them. If local regulatory agencies approve the drug, the company will ensure it's access to the pharmaceutical market of these states.